Graham Capital Management L.P. lifted its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 582.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 100,270 shares of the company's stock after purchasing an additional 85,576 shares during the quarter. Graham Capital Management L.P. owned about 0.06% of Certara worth $1,068,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the business. Blue Trust Inc. lifted its position in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after purchasing an additional 822 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Certara by 3.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company's stock worth $253,000 after purchasing an additional 823 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after purchasing an additional 1,047 shares in the last quarter. Bank of Montreal Can lifted its position in shares of Certara by 9.1% during the fourth quarter. Bank of Montreal Can now owns 19,943 shares of the company's stock worth $212,000 after purchasing an additional 1,670 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC lifted its position in shares of Certara by 20.5% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,943 shares of the company's stock worth $138,000 after purchasing an additional 2,202 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.
Wall Street Analyst Weigh In
CERT has been the topic of several research reports. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. KeyCorp raised their target price on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Robert W. Baird raised their target price on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Finally, Stephens reaffirmed an "overweight" rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $15.67.
Check Out Our Latest Stock Analysis on Certara
Certara Stock Performance
Shares of Certara stock opened at $12.14 on Wednesday. The firm has a market capitalization of $1.97 billion, a P/E ratio of -60.70, a P/E/G ratio of 9.29 and a beta of 1.57. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $17.76. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm's 50 day moving average is $11.69 and its two-hundred day moving average is $11.70.
Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm's revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 earnings per share. Research analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.
Certara Company Profile
(
Free Report)
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Certara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.
While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
